|
|||||
|
|
Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia |
|
| Authors: | Samuelsson Jan Mutschler Manuel Birgegård Gunnar Gram-Hansen Poul Björkholm Magnus Pahl Heike L |
| Abstract: | Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |